GLP1 Receptor Agonist Induced Guttate Psoriasis in an Adult Female

Main Article Content

Savannah Cook
Indiana University School of Medicine

Thomas Selby
Indiana University School of Medicine; Deaconess Dermatology

Keywords

Glucagon-like-peptide-1, GLP-1 agonists, cutaneous adverse effects, Tirzepatide, psoriasis, guttate psoriasis

Abstract

With increasing use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), it is important to recognize possible adverse effects. While most cutaneous GLP-1RAs side effects are related to injection site reactions, there are several documented instances of rare cutaneous effects. We present a novel case of tirzepatide-induced psoriasis resolved with risankizumab-rzaa treatment. 

References

1. Yeo YH, Rezaie A, Hsieh TY, Hu X, Gaddam S, Ma KS; Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group. Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis. Ann Intern Med. 2024 Jul 23. doi: 10.7326/M24-0019. Epub ahead of print. PMID: 39038291.

2. Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P, Nandula SA, Nawaz FK, Tracey K, Yang H, LeRoith D, Brownstein MJ, Roth J. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023 May 17;14:1148209. doi: 10.3389/fimmu.2023.1148209. PMID: 37266425; PMCID: PMC10230051.

3. Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014 Fall-Winter;11(3-4):202-30. doi: 10.1900/RDS.2014.11.202. Epub 2015 Feb 10. PMID: 26177483; PMCID: PMC5397288.

4. Salazar CE, Patil MK, Aihie O, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Arch Dermatol Res. 2024 May 25;316(6):248. doi: 10.1007/s00403-024-02969-3. PMID: 38795152.

5. Grän F, Kerstan A, Serfling E, Goebeler M, Muhammad K. Current Developments in the Immunology of Psoriasis. Yale J Biol Med. 2020 Mar 27;93(1):97-110. PMID: 32226340; PMCID: PMC7087066.

6. Lin L, Xu X, Yu Y, Ye H, He X, Chen S, Chen X, Shao Z, Chen P. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022 May;33(3):1428-1434. doi: 10.1080/09546634.2020.1826392. Epub 2020 Sep 24. PMID: 32962477.

7. Costanzo G, Curatolo S, Busà B, Belfiore A, Gullo D. Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. Endocrinol Diabetes Metab Case Rep. 2021 Aug 1;2021:21-0007. doi: 10.1530/EDM-21-0007. Epub ahead of print. PMID: 34463640; PMCID: PMC8428016.

8. Bostan E, Akdogan N, Gokoz O. Paradoxical new-onset psoriasiform dermatitis associated with exenatide administration. Int J Dermatol. 2022 Mar;61(3):e112-e114. doi:10.1111/ijd.15863. Epub 2021 Aug 17. PMID: 34403495.

9. Wang Y, Deng F, Zhong X, Du Y, Fan X, Su H, Pan T. Dulaglutide provides protection against sepsis-induced lung injury in mice by inhibiting inflammation and apoptosis. Eur J Pharmacol. 2023 Jun 15;949:175730. doi: 10.1016/j.ejphar.2023.175730. Epub 2023 Apr 14. PMID: 37062504.

10. Hachuła M, Kosowski M, Ryl S, Basiak M, Okopień B. Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process. Int J Mol Sci. 2024 Feb 3;25(3):1854. doi: 10.3390/ijms25031854. PMID: 38339133; PMCID: PMC10855444.

11. Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol. 2022 May;86(5):1080-1091. doi: 10.1016/j.jaad.2020.12.010. Epub 2020 Dec 8. PMID: 33307146.

12. Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, Lapointe AK, French LE, Vernez M, Gilliet M. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018 Jan 2;9(1):25. doi: 10.1038/s41467-017-02466-4. PMID: 29295985; PMCID: PMC5750213.

Article Sidebar

PDF
Published
2025-05-12
DOI: https://doi.org/10.25251/skin.9.3.9

Article Details

How to Cite
1.
GLP1 Receptor Agonist Induced Guttate Psoriasis in an Adult Female. J of Skin. 2025;9(3):2334-2338. doi:10.25251/skin.9.3.9
Issue
Vol. 9 No. 3 (2025): May 2025 Issue
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.